[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340494-105":59,"doc-detail-340494-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","navigating-the-implementation-gap-trastuzumabs-journey-from-health-insurance-to-patient-access","Navigating the implementation gap - Trastuzumab’s journey from health insurance to patient access","","Insurance policy shifts and pricing adjustments shape Trastuzumab use in China, where high costs often block access to this breast cancer monoclonal antibody. A retrospective hospital study evaluated HER2-positive patients from May 2013 to December 2022, analyzing how insurance implementation and affordability affected drug uptake and the use of FISH testing needed to confirm eligibility. Findings showed utilization rose after coverage expansion and price reductions, while uncovered FISH testing created ongoing barriers, especially for rural patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/navigating-the-implementation-gap-trastuzumabs-journey-from-health-insurance-to-patient-access/340494/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/navigating-the-implementation-gap-trastuzumabs-journey-from-health-insurance-to-patient-access/340494.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study investigate regarding Trastuzumab access in China?","Question",{"text":112,"@type":113},"The study examines how changes in medical insurance policies and price adjustments influence Trastuzumab utilization, focusing on implementation challenges affecting accessibility and affordability.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients grouped in the retrospective analysis?",{"text":117,"@type":113},"Patients were stratified by their CerbB2 indicator; those with CerbB2 2+ required further FISH testing to confirm Trastuzumab eligibility.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings on Trastuzumab and FISH testing utilization?",{"text":121,"@type":113},"After insurance coverage expansion and later a 2020 price reduction, Trastuzumab utilization increased substantially. The FISH test was not covered by health insurance and became available locally only after Trastuzumab reached the city, leading to ongoing uptake barriers, particularly for rural patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340494,1790217064,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","Yang et al. Global Health Research and Policy (2024) 9:50  \n[https://doi.org/10.1186/s41256-024-00384-9](https://doi.org/10.1186/s41256-024-00384-9)  \nGlobal Health Research and Policy  \n RESEARCH Open Access  \nNavigating the implementation gap  \nforTrastuzumab’s journey from health insurance to patient access: a preliminary study in a hospital in China  \nXingxia Yang1†, Yufei Jia2†, Jianhong Xu2, Qin Zhou3, Qian Long2,4, Yi Yang1, Yunguo Liu2, Juanying Zhu1* and Xiaochen Zhang2,5*  \nAbstract  \nBackground Trastuzumab, a monoclonal antibody for breast cancer, faces global accessibility challenges, primarily due to high costs. This study examines how changes in medical insurance policies and price adjustments influence Trastuzumab utilization in China, focusing on implementation challenges and their impact on drug accessibility and affordability.  \nMethods This retrospective study investigated Trastuzumab utilization among HER2-positive breast cancer patients at a tertiary hospital from May 2013 to December 2022 in JX, a prefecture-level city in eastern China. Patients were stratified based on their CerbB2 indicator, because those with a 2 + CerbB2 status require further FISH testing to confirm Trastuzumab eligibility. We analyzed the utilization rates of both FISH test and Trastuzumab using logistic regressions, identifying factors that influence their usage.  \nResults 766 patients were included. The utilization rate of Trastuzumab among patients with CerbB2 3+ rose  \nfrom 40.40 to 77 . 94% in September 2017 following the expansion of insurance coverage, and further increased to 90.41% after a price reduction in 2020. The FISH test was not covered by health insurance, and it was not available in the local hospital until Trastuzumab became available in JX city. For patients with CerbB2 2+, the proportion undergoing the FISH test increased dramatically from 8.89 to 82. 08% after the price reduction in 2020. The mere inclusion into basic medical insurance, regardless of insurance types, significantly increased the utilization of Trastuzumaband the FISH test. However, rural patients in JX city are still facing financial burdens with Trastuzumab’s out-of-pocket cost accounting for 62. 9% of their annual disposable income in 2020.  \nConclusions Our findings indicate that insurance coverage and price reduction significantly increased Trastuzumab utilization. However, failure to improve the accessibility of the FISH test can pose challenges in enhancing the uptake of Trastuzumab among eligible patients. With the expiration of Trastuzumab’s patent and the development  \n†* Xingxia Yang andYufei Jia contributed equally to this work and co-share first authorship.  \n*Correspondence: Juanying Zhu [2720597818@qq.com](2720597818@qq.com)[ ](2720597818@qq.com)Xiaochen Zhang  \n[xiaochen.zhang@dukekunshan.edu.cn](xiaochen.zhang@dukekunshan.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nYang et al. Global Health Research and Policy (2024) 9:50 Page 2 of 12  \nof","cbCaib7qoptPi1ZS","https://ap.wps.com/l/cbCaib7qoptPi1ZS","pdf",1021639,12,"English","# Background\n## Trastuzumab and HER2-positive breast cancer access challenges\n# Methods\n## Study design and patient stratification\n# Results\n## Utilization changes after insurance expansion and price reductions\n## FISH test coverage and availability\n## Financial burden for rural patients\n# Conclusions\n## Implications for policy and treatment access","[{\"question\":\"What problem does the study investigate regarding Trastuzumab access in China?\",\"answer\":\"The study examines how changes in medical insurance policies and price adjustments influence Trastuzumab utilization, focusing on implementation challenges affecting accessibility and affordability.\"},{\"question\":\"How were patients grouped in the retrospective analysis?\",\"answer\":\"Patients were stratified by their CerbB2 indicator; those with CerbB2 2+ required further FISH testing to confirm Trastuzumab eligibility.\"},{\"question\":\"What were the key findings on Trastuzumab and FISH testing utilization?\",\"answer\":\"After insurance coverage expansion and later a 2020 price reduction, Trastuzumab utilization increased substantially. The FISH test was not covered by health insurance and became available locally only after Trastuzumab reached the city, leading to ongoing uptake barriers, particularly for rural patients.\"}]","Navigating the implementation gap - Trastuzumab’s journey from health insurance to patient access | PDF",1790036872,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f0f88c08aa86c6733940c3a24cf96d2.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee8f2a5274d2941f08390fdf7e105174.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be8a77a320c2bf1d98210a1f74daf1ff.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8acae1b5196e707235dabf4e335e787c.webp",980,1301]